CRA Insights

The pharmaceutical industry under the new US administration: policy, the political agenda, (and pricing)

January 11, 2017

In this issue of Insights, we summarize a recent discussion held with a number of pharmaceutical companies on US health policy, potential priorities for the Trump administration, and yes, pricing. Tim Wilsdon, an expert in international policy issues affecting the development and commercialization of medicines, led the discussion. 
To read more, click the link below.

Meet the authors